3SBio Inc. Announces Extraordinary General Meeting of Shareholders

      3SBio Inc. Announces Extraordinary General Meeting of Shareholders

PR Newswire

SHENYANG, China, March 24, 2013

SHENYANG, China, March 24, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX)
("3SBio" or the "Company"), a leading China-based biotechnology company
focused on researching, developing, manufacturing and marketing
biopharmaceutical products, today announced that it has called an
extraordinary general meeting of shareholders (the "EGM"), to be held at 10:00
a.m. on April 25, 2013 (Beijing time). The meeting will be held at 15/A-D,
Huaxin International Tower, No. 219, Qingnian Ave., Shenhe District, Shenyang
110016, People's Republic of China, to consider and vote on the proposal to
adopt the previously announced agreement and plan of merger dated February 8,
2013, among Decade Sunshine Limited, an exempted company with limited
liability incorporated under the laws of the Cayman Islands ("Parent"), Decade
Sunshine Merger Sub, an exempted company with limited liability incorporated
under the laws of the Cayman Islands and a direct wholly owned subsidiary of
Parent ("Merger Sub"), and the Company (the "Merger Agreement"), pursuant to
which Merger Sub will be merged with and into the Company, with the Company
surviving the merger as a wholly-owned subsidiary of Parent (the "Merger").
If completed, the Merger would result in the Company becoming a privately-held
company and its American Depository Shares ("ADSs") would no longer be listed
on the NASDAQ Global Market. The Company's Board of Directors, acting upon
the unanimous recommendation of an independent committee formed by the Board
of Directors, approved the Merger Agreement and the merger contemplated in the
Merger Agreement and resolved to recommend that the Company's shareholders
vote to approve and authorize the Merger Agreement and the merger.

Shareholders of record as of the close of business in the Cayman Islands on
April 12, 2013 will be entitled to vote at the EGM. The record date for ADS
holders entitled to instruct JPMorgan Chase Bank, N.A., the ADS depositary, to
vote the shares represented by the ADSs is the close of business in New York
City on March 25, 2013. Additional information regarding the EGM and the
Merger Agreement can be found in the Transaction Statement on Schedule 13E-3,
and the proxy statement attached as Exhibit (a)-(1) thereto, filed with the
Securities and Exchange Commission (the "SEC"), which can be obtained from the
SEC's website (http://www.sec.gov).

INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY
THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC, AS
THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND
RELATED MATTERS.

This announcement is neither a solicitation of proxy, an offer to purchase nor
a solicitation of an offer to sell any securities and it is not a substitute
for any proxy statement or other filings that have been or will be made with
the SEC.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused
on researching, developing, manufacturing and marketing biopharmaceutical
products primarily in China. Its focus is on addressing large markets with
significant unmet medical needs in nephrology, oncology, supportive cancer
care, inflammation and infectious diseases. With headquarters and
GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over
800 people. Shares trade in the form of ADSs on the NASDAQ global market
under the ticker symbol "SSRX". Please see www.3SBio.com for more
information.

For investor and media inquiries, please contact:

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com

SOURCE 3SBio Inc.

Website: http://www.3sbio.com
 
Press spacebar to pause and continue. Press esc to stop.